Clinical trial of Sailuotong (SLT) for Vascular Dementia or Alzheimer’s Disease with evidence of cerebrovascular disease trial
Status: Recruiting
Sponsor: Australia Shineway Technology Pty Ltd
Dementia Trials Australia (DTAus) is the key body in promoting, facilitating and coordinating both commercially-sponsored and investigator-initiated dementia and cognition trials in Australia. The network provides an effective communication channel between local clinicians and study sponsors and has played an increasingly important role in attracting studies throughout Australasia. A central part of what the DTAus does is to assist sponsors in determining the feasibility of conducting new studies in our region and to set appropriate recruitment forecasts. We do this by reviewing the study protocol, budget and study logistics, and number of Australian sites required in the context of current competing studies. This process allows the early identification of potential problems with local ethics committees and draws on an intimate understanding of local capabilities.
Clinical trial of Sailuotong (SLT) for Vascular Dementia or Alzheimer’s Disease with evidence of cerebrovascular disease trial
Status: Recruiting
Sponsor: Australia Shineway Technology Pty Ltd
Phase 2 Study of BIIB092 in Participants With Early Alzheimer’s Disease (TANGO).
Status: Active
Sponsor: Biogen
A Biomarker-directed Study of XPro1595 in Patients With Mild to Moderate Alzheimer’s
Status: Recruiting
Sponsor: ImmuneBio
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer’s Disease.
Status: Recruiting
Sponsor: Cognition Therapeutics
Coronavirus Disease 2019 (COVID-19) is a disease caused by a new form of coronavirus which developed into a pandemic in early 2020 bringing new challenges for health care workers and research staff.
As an organisation our number one priority is the health and safety of site staff, our clinical trial participants, the broader community and trial integrity. The COVID -19 situation is continually changing and research sites across Australia have succeeded in the implementation of contingency measures to manage study disruption. Australian sites are actively managing research activities including trial participation according to relevant State and National guidelines.
DTAus would like to highlight that the highly qualified clinical sites in Australia are currently undertaking clinical trials and the safety and well-being of clinical trial participants, visitors, clinical staff and quality of trials will always be paramount. DTAus are committed to supporting the vital work undertaken by our clinical trial sites with clinical trials continuing to take place across Australia.